ClinicalSudden DeathCauses and clinical consequences of inappropriate shocks experienced by patients wearing a cardioverter-defibrillator
Graphical abstract
Introduction
The wearable cardioverter-defibrillator (WCD) prevents sudden cardiac death in at-risk patients who are not candidates for an implantable defibrillator.1, 2, 3, 4, 5, 6, 7 As suggested by VEST (Vest Prevention of Early Sudden Death Trial),3 the efficacy of the WCS in clinical practice may be significantly impacted by patient noncompliance caused by inappropriate shocks (IAS), frequent false alarms, and device discomfort. WCD IAS may induce ventricular fibrillation (VF) or ventricular tachycardia (VT) or cause asystolic cardiac arrest,4,8 and they often result in an emergency room visit or hospitalization. Importantly, IAS may precipitate WCD discontinuation by the patient or provider.
The LifeVest® (ZOLL Medical Corp, Pittsburgh, PA) was introduced in 2001, and the current LifeVest 4000 WCD has been available since 2009. In a previous study, we described deaths caused by postshock asystole following WCD IAS.8 The purpose of this study was to assess IAS in ambulatory patients who survived IAS delivered by the LifeVest WCD and were reported to the Food and Drug Administration (FDA) during 2021 and 2022.
Section snippets
Methods
The Allina Institutional Review Board determined that this study did not constitute human subjects research because it utilized a publicly available database that only includes de-identified data.
Results
During 2021 and 2022, the FDA received 2568 adverse event reports from the manufacturer, describing 3929 IAS (average IAS per event: 1.5 ± 1.9; range 1–48) delivered by the LifeVest WCD 4000 that were experienced by nonhospitalized patients. All except 9 events occurred in the United States. Of the 2071 IAS events during which the patient's mental status was known, 1909 patients (92.3%) were conscious, 106 (5.1%) were unconscious, 52 (2.5%) were sleeping, and 4 (0.2%) appeared confused.
Discussion
The results of this study suggest that LifeVest WCD IAS are caused equally by AF/RVR, SVT, or NSVT and signals generated by motion or oversensing of low-level electrical artifacts. The incidence of these IAS is not known, but 2568 individual IAS events were reported by the manufacturer to the FDA during 2021 and 2022. In addition to the pain and discomfort of high-voltage shocks, we found IAS could be arrhythmogenic and result in physical injuries. Perhaps most importantly, IAS caused 17% of
Conclusion
The LifeVest wearable cardioverter-defibrillator may deliver IAS caused by AF, SVT, NSVT/VF, motion artifacts, and oversensing of low-level electrical signals. These shocks can be arrhythmogenic, result in physical injuries, precipitate discontinuation of the WCD, and consume expensive medical resources. Improved WCD sensing technology, rhythm discrimination, and methods to abort IAS are needed.
Acknowledgment
We are grateful to the Joseph F. Novogratz family for its support of this research through the Heart Rhythm Science Center of the Minneapolis heart Institute Foundation.
References (19)
- et al.
Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance and survival
J Am Coll Cardiol
(2010) - et al.
Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death
JACC Clin Electrophysiol
(2019) - et al.
Benefit of the wearable cardioverter-defibrillator in protecting patients after implantable cardioverter-defibrillator explant
JACC Clin Electrophysiol
(2017) - et al.
Wearable cardioverter-defibrillator use in patients perceived to be at high risk early post-myocardial infarction
J Am Coll Cardiol
(2013) - et al.
Utility of the wearable cardioverter-defibrillator in patients with newly diagnosed cardiomyopathy
J Am Coll Cardiol
(2015) - et al.
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Circulation
(2018) - et al.
Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death
Circulation
(2016) - et al.
Wearable cardioverter-defibrillator after myocardial infarction
N Engl J Med
(2018) - et al.
Post-shock asystole in patients dying out-of-hospital while wearing a cardioverter-defibrillator
JACC Clin Electrophysiol February
(2023)
Cited by (1)
The Role of the Wearable Defibrillator in Heart Failure
2024, Current Heart Failure Reports
Funding Sources: Minneapolis Heart Institute Foundation, Minneapolis, Minnesota.
Disclosures: The authors have no conflicts of interest to disclose.